Yazar "Sermet, Abdurrahman" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats(Elsevier Science Inc, 2007) Obay, Basra Deniz; Tasdemir, Ezel; Tuemer, Cemil; Bilgin, Hakki Murat; Sermet, AbdurrahmanIt is well known that neuropeptide Y (NPY) and gamma-aminobutyric acid (GABA) exert antiepileptic effects in animal models. It has recently been shown that ghrelin neurons increase the activities of GABA and NPY in the brain. Therefore it can be said that ghrelin is an antiepileptic agent. In this study we aimed to investigate the antiepileptic effect of ghrelin in an acute experimental epilepsy model in pentylenetetrazole (PTZ) injected rats. Adult male Wistar albino rats were divided into a control group and four experimental groups with seven rats in each group. In order to generate epileptic seizures, PTZ (50 mg/kg) was injected intraperitone ally. The experimental groups received intraperitoneal injections of ghrelin at doses of 20,40, 60 and 80 mu g/kg 30 min before PTZ injection. After PTZ injection, the latencies were separated into three components: first myoclonic jerk, generalized clonic seizures and tonic generalized extension. The injection of 50 mg/kg PTZ-induced epileptic seizures in the control group. The onset-times of the three characteristic behavioral changes were significantly delayed and the duration of tonic generalized extension was diminished by dose-dependent ghrelin administration. Our results demonstrated that ghrelin suppresses the onset time of PTZ-induced seizures. In the light of our current knowledge, it seems that ghrelin may be considered as an antiepileptic drug. (c) 2007 Elsevier Inc. All rights reserved.Öğe Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model(Sci Printers & Publ Inc, 2015) Ezel, Tasdemir; Kocyigit, Yuksel; Deveci, Engin; Atamer, Yildiz; Sermet, Abdurrahman; Uysal, Ersin; Aktas, Ayfer[Abstract Not Available]Öğe Comparison of the anti-diabetic effects of resveratrol, gliclazide and losartan in streptozotocin-induced experimental diabetes(Taylor & Francis Ltd, 2015) Yazgan, Umit Can; Tasdemir, Ezel; Bilgin, Hakki Murat; Obay, Basra Deniz; Sermet, Abdurrahman; Elbey, BilalAim: The aim of this study was to compare the effect of the resveratrol with gliclazide and losartan in streptozotocin induced diabetic rats. Materials and methods: Adult male Wistar albino rats were divided into five groups of seven rats each. Diabetes was induced with a single intraperitoneal (i.p.) injection of streptozotocin (55mg/kg). Rats with blood glucose levels above 250mg/dl after 48h of streptozotocin injection were included in the diabetic group. Gliclazide and resveratrol were administered for 3 weeks at 5mg/kg per day and losartan was administered for 3 weeks at 30mg/kg per day in an oral aqueous suspension. At the end of the third week all rats were euthanized and fasting blood glucose, HbA1c and the metabolic activity of the hepatic enzymes hexokinase and glucose-6 phosphate dehydrogenase were measured in tail blood and liver specimens. All parameters were quantified using an ELISA plate reader. Results: Resveratrol and gliclazide significantly reduced both blood glucose levels and HbA1c levels in diabetic rats (p<0.001). However, losartan did not exhibit the same effects (p<0.05). The enzymatic activity of the liver enzymes hexokinase, glucose-6 phosphate dehydrogenase, fructose 1,6-biphosphatase, pyruvate kinase and glucose-6 phosphatase were enhanced by resveratrol and gliclazide, while losartan treatment was not associated with significant changes in liver carbohydrate metabolism. Conclusion: Resveratrol was not effective in improving liver carbohydrate metabolism relative to gliclazide, a drug widely used to treat diabetes. Dose-response profile of resveratrol remains indeterminate and additional studies may be necessary to determine effective dosing in diabetes.Öğe Effect of ghrelin administration on phagocytic activity in acute cold-restraint stress exposed rats(Elsevier, 2007) Tumer, Cemil; Bilgin, Hakki Murat; Obay, Basra Deniz; Diken, Huda; Tasdemir, Ezel; Sermet, AbdurrahmanGhrelin, an endogenous ligand for growth hormone secretagogue receptor, was identified in the rat stomach. This peptide acts through nitric oxide (NO) by expressing endothelial nitric oxide synthase (eNOS) and down regulating inducible nitric oxide synthase (NOS) at its gastroproprotective effect against restraint stress induced damage. Recently the glirelin receptor has also been detected in peripheral systems including immune tissue. We have investigated the possible effect of glirelin on phagocytic activity of peritoneal macrophages in acute coldrestraint stress (ACRS) exposed rats. The rats were divided into control, stress and ghrelin groups. In ghrelin groups, single dose and three days consecutive dose of ghrelin (20 mu g/kg. i.p.) were applied to rats that were exposed to ACRS for 4 h. I rut of saline was injected i.p. after ACRS for 3 consecutive days to the rats of the stress groups. Ghrelin administration reduced the increased phagocytic activity induced by ACRS. We conclude that ghrelin exerts an important role at macrophage phagocytic activity in ACRS exposed rats. (c) 2006 Elsevier B.V. All rights reserved.Öğe Investigation of the Serum Visfatin, Fetuin A and Eotaxin Levels in Patients with Type 2 Diabetes Mellitus(Wiley, 2017) Kaya, Hacer; Sermet, Abdurrahman; Tasdemir, Ezel; Pekkolay, Zafer[Abstract Not Available]Öğe The role of monoamine oxidases in diabetic nephropathy rat model Diabetic nephropathy model(Bayrakol Medical Publisher, 2019) Tasdemir, Ezel; Sermet, AbdurrahmanAim: Diabetic nephropathy (DN) is a serious complication that can lead to renal failure in many diabetic patients. Although there are multiple mechanisms related to the pathogenesis of the disease, reactive oxygen species (ROS) play an important role in its etiology. It has been suggested that monoamine oxidases (MAOs) as an intracellularly important ROS source may cause nephropathy by contributing to redox state imbalance in the kidney of diabetics. We investigated the role of monoaminoxidase-A (MAO-A) and monoaminoxidase-B (MAO-B) in the pathogenesis of diabetic nephropathy (DN) induced by streptozotocin (STZ) in rats. We also tried to demonstrate the importance of MAO-A or MAO-B inhibition to prevent the development and progression of DN. Material and Method: Twenty-eight male Wistar albino rats were divided into four groups as normal control and three diabetic groups. A single dose of STZ was given to the peritoneal cavity of rats to induce diabetes. One of the diabetic groups was treated with MAO-A inhibitor(moclobemide, 5 mg/kg/day), another group MAO-B inhibitor, (rasagiline, 10 mg/kg/day), while those included in the DN group were not treated. After the eight-week treatment period, urine samples were collected with a metabolic cage to measure N -acethyl-b-glucosaminidase (NAG), g-glutamyltranspeptidase (GGT), creatinine, glucosuria and proteinuria, and then the animals were anesthetized and sacrificed by cardiac puncture and the kidneys were taken. Blood glucose, BUN, serum creatinine, renal MAO-A, MAO-B, superoxide dismutase (SOD) and catalase (CAT) activity and lipid peroxidation (MDA) were determined by spectrophotometric or ELISA method. Results: The untreated diabetic rats showed nephropathy symptoms such as high serum creatinine, proteinuria, glucosuria and high urinary NAG and GGT. However, renal MAO-A, MAO-B, SOD and CAT activity and MDA levels increased in DN rats. Although moclobemide or rasagiline treatment significantly reduced nephropathic findings and high renal MAO-A and MAO-B activity in diabetic rats, MAO-A inhibition showed more effect than MAO-B. Discussion: The results indicate that the renal MAO-A and MAO-B activity playsan important pathophysiological role, which is responsible for the development and progression of DN, and that MAO-A inhibition is more effective than MAO-B to prevent the formation of DN in diabetic rats.